Surgery at this point has been proposed as a means of reducing tumour burden, promoting a durable response to immunotherapy in patients with demonstrated tumour regression or stable disease after this time. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int. J. Cancer 2005; 117: 316 - 25. 9 Okamura T, Kanda T, Hirota S, Nishimura A, Kawahara M, Nikkuni K. Imatinib therapy for a patient with metastasis of colonic gastrointestinal stromal tumor: report of a case. [Extracted from the article]